Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations

Cancer Immunology, Immunotherapy

Volumn 59, Issue 3, 2010, Pages 397-408

  Boehm, Amanda L ^a   Higgins, Jack ^a   Franzusoff, Alex ^b   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GlobeImmune Inc   (United States)

Author keywords

Antitumor immunity; Carcinoembryonic antigen (CEA); Saccharomyces cerevisiae; T cell populations; Vaccinia

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; FOWLPOX VIRUS VACCINE; FUNGUS VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; SACCHAROMYCES CEREVISIAE VACCINE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION REGULATION; INNATE IMMUNITY; LUNG METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; UPREGULATION; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE; CELL LINE, TUMOR; CHEMOKINES; CYTOKINES; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POXVIRIDAE; SACCHAROMYCES CEREVISIAE; T-LYMPHOCYTES; VACCINATION;

EID: 73349104629     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0759-7     Document Type: Article

References (41)

1. B Weide C Garbe HG Rammensee S Pascolo 2008 Plasmid DNA- and messenger RNA-based anti-cancer vaccination Immunol Lett 115 1 33 42 10.1016/j.imlet.2007. 09.012 1:CAS:528:DC%2BD1cXhtlejsw%3D%3D 18006079 (Pubitemid 350298588)
2. A Riezebos-Brilman M Walczak J Regts MG Rots G Kamps B Dontje, et al. 2007 A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer Gene Ther 14 24 1695 1704 10.1038/sj.gt.3303036 1:CAS:528:DC%2BD2sXhtl2gsrvM 17928874 (Pubitemid 350238446)
3. TI Naslund C Uyttenhove EK Nordstrom D Colau G Warnier M Jondal, et al. 2007 Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor J Immunol 178 11 6761 6769 17513723
4. LM Mylin TD Schell D Roberts M Epler A Boesteanu EJ Collins, et al. 2000 Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes J Virol 74 15 6922 6934 10.1128/JVI.74.15.6922-6934.2000 1:CAS:528:DC%2BD3cXkvFCmtLw%3D 10888631 (Pubitemid 30470675)
5. J Millar D Dissanayake TC Yang N Grinshtein C Evelegh Y Wan, et al. 2007 The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector Cell Immunol 250 1-2 55 67 10.1016/j.cellimm.2008.01.005 1:CAS:528:DC%2BD1cXktVCntrk%3D 18313652
6. JW Hodge DJ Poole WM Aarts A Gomez Yafal L Gritz J Schlom 2003 Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses Cancer Res 63 22 7942 7949 1:CAS:528:DC%2BD3sXptFOltLo%3D 14633725
7. T Chan A Sami A El-Gayed X Guo J Xiang 2006 HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination Gene Ther 13 19 1391 1402 10.1038/sj.gt.3302797 1:CAS:528:DC%2BD28Xps1yjs78%3D 16724093 (Pubitemid 44420634)
8. DR Casimiro L Chen TM Fu RK Evans MJ Caulfield ME Davies, et al. 2003 Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene J Virol 77 11 6305 6313 10.1128/JVI.77.11.6305-6313.2003 1:CAS:528:DC%2BD3sXktV2nsrw%3D 12743287 (Pubitemid 36588400)
9. R Bos S van Duikeren T van Hall MM Lauwen M Parrington NL Berinstein, et al. 2007 Characterization of antigen-specific immune responses induced by canarypox virus vaccines J Immunol 179 9 6115 6122 1:CAS:528: DC%2BD2sXhtFyksr%2FN 17947686
10. JW Hodge H Sabzevari AG Yafal L Gritz MG Lorenz J Schlom 1999 A triad of costimulatory molecules synergize to amplify T-cell activation Cancer Res 59 22 5800 5807 1:CAS:528:DyaK1MXnslyhu7g%3D 10582702
11. JW Hodge DW Grosenbach WM Aarts DJ Poole J Schlom 2003 Vaccine therapy of established tumors in the absence of autoimmunity Clin Cancer Res 9 5 1837 1849 1:CAS:528:DC%2BD3sXjsFeitLs%3D 12738742
12. DW Grosenbach JC Barrientos J Schlom JW Hodge 2001 Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects Cancer Res 61 11 4497 4505 1:CAS:528:DC%2BD3MXktlWjs7o%3D 11389081
13. JW Greiner H Zeytin MR Anver J Schlom 2002 Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity Cancer Res 62 23 6944 6951 1:CAS:528:DC%2BD38XpsVahsLk%3D 12460911
14. PM Arlen JL Gulley RA Madan JW Hodge J Schlom 2007 Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy Crit Rev Immunol 27 5 451 462 1:CAS:528:DC%2BD2sXhsVCmsbzI 18197807
15. MB Bernstein M Chakraborty EK Wansley Z Guo A Franzusoff S Mostbock, et al. 2008 Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells Vaccine 26 4 509 521 10.1016/j.vaccine.2007.11.033 1:CAS:528:DC%2BD1cXlt1Kitg%3D%3D 18155327
16. EK Wansley M Chakraborty KW Hance MB Bernstein AL Boehm Z Guo, et al. 2008 Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses Clin Cancer Res 14 13 4316 4325 10.1158/1078-0432.CCR-08-0393 1:CAS:528: DC%2BD1cXnvFyksL8%3D 18594015
17. PF Robbins JA Kantor M Salgaller PH Hand PD Fernsten J Schlom 1991 Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line Cancer Res 51 14 3657 3662 1:CAS:528: DyaK3MXlt12jsbc%3D 1712245
18. E Kass DL Panicali G Mazzara J Schlom JW Greiner 2001 Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant Cancer Res 61 1 206 214 1:CAS:528: DC%2BD3MXlsl2ktw%3D%3D 11196163
19. AA Haller GM Lauer TH King C Kemmler V Fiolkoski Y Lu, et al. 2007 Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and core proteins Vaccine 25 8 1452 1463 10.1016/j.vaccine.2006.10.035 1:CAS:528:DC%2BD2sXls1Ojsw%3D%3D 17098335 (Pubitemid 46074294)
20. C Pannetier M Cochet S Darche A Casrouge M Zoller P Kourilsky 1993 The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments Proc Natl Acad Sci USA 90 9 4319 4323 10.1073/pnas.90.9.4319 1:CAS:528:DyaK3sXktVKrsrY%3D 8483950
21. B Arden JL Klotz G Siu LE Hood 1985 Diversity and structure of genes of the alpha family of mouse T-cell antigen receptor Nature 316 6031 783 787 10.1038/316783a0 1:CAS:528:DyaL2MXltlKgtr4%3D 3839904 (Pubitemid 15003738)
22. JW Hodge M Chakraborty C Kudo-Saito CT Garnett J Schlom 2005 Multiple costimulatory modalities enhance CTL avidity J Immunol 174 10 5994 6004 1:CAS:528:DC%2BD2MXjvV2msbY%3D 15879092
23. M Derby M Alexander-Miller R Tse J Berzofsky 2001 High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL J Immunol 166 3 1690 1697 1:CAS:528: DC%2BD3MXhtVSjurk%3D 11160212
24. Wunderlich J, Shearer G (1994) Induction and measurement of cytotoxic T lymphocyte activity. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W (eds) Current protocols in immunology. Wiley, Hoboken, NJ
25. H Wexler 1966 Accurate identification of experimental pulmonary metastases J Natl Cancer Inst 36 4 641 645 1:STN:280:DyaF287js1ylsg%3D%3D 4160686
26. ME Dudley LT Ngo J Westwood JR Wunderlich SA Rosenberg 2000 T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes Cancer J 6 2 69 77 1:STN:280: DC%2BD3crhtFGnug%3D%3D 11069222
27. V Dutoit V Rubio-Godoy PY Dietrich AL Quiqueres V Schnuriger D Rimoldi, et al. 2001 Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity Cancer Res 61 15 5850 5856 1:CAS:528:DC%2BD3MXlvVCgurs%3D 11479225
28. H Echchakir I Vergnon G Dorothee D Grunenwald S Chouaib F Mami-Chouaib 2000 Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung Int Immunol 12 4 537 546 10.1093/intimm/12.4.537 1:CAS:528:DC%2BD3cXisl2hs7k%3D 10744655
29. L Ferradini S Roman-Roman J Azocar MF Avril S Viel F Triebel, et al. 1992 Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis Cancer Res 52 17 4649 4654 1:CAS:528:DyaK38XlvV2qsrk%3D 1324789
30. I Messaoudi JA Guevara Patino R Dyall J LeMaoult J Nikolich-Zugich 2002 Direct link between MHC polymorphism, T cell avidity, and diversity in immune defense Science 298 5599 1797 1800 10.1126/science.1076064 1:CAS:528: DC%2BD38XovFKmsLk%3D 12459592 (Pubitemid 35404125)
31. J Nikolich-Zugich MK Slifka I Messaoudi 2004 The many important facets of T-cell repertoire diversity Nat Rev Immunol 4 2 123 132 10.1038/nri1292 1:CAS:528:DC%2BD2cXhsVKqsL0%3D 15040585
32. C Sportes FT Hakim SA Memon H Zhang KS Chua MR Brown, et al. 2008 Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets J Exp Med 205 7 1701 1714 10.1084/jem.20071681 1:CAS:528:DC%2BD1cXosVKktLs%3D 18573906 (Pubitemid 351962032)
33. X Zhou DY Jun AM Thomas X Huang LQ Huang J Mautner, et al. 2005 Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine Cancer Res 65 3 1079 1088 10.1158/0008-5472.CAN-04-3509 1:CAS:528:DC%2BD2MXhtVWnurs%3D 15705910 (Pubitemid 40911190)
34. JW Hodge JP McLaughlin JA Kantor J Schlom 1997 Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses Vaccine 15 6-7 759 768 10.1016/S0264-410X(96)00238-1 1:CAS:528:DyaK2sXktFGqu7o%3D 9178479 (Pubitemid 27240492)
35. JL Marshall RJ Hoyer MA Toomey K Faraguna P Chang E Richmond, et al. 2000 Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses J Clin Oncol 18 23 3964 3973 1:STN:280:DC%2BD3M%2Fnt1GisQ%3D%3D 11099326
36. L Wu WP Kong GJ Nabel 2005 Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens J Virol 79 13 8024 8031 10.1128/JVI.79.13.8024-8031.2005 1:CAS:528:DC%2BD2MXlslGjt7k%3D 15956548 (Pubitemid 40853506)
37. P Pancholi Q Liu N Tricoche P Zhang ME Perkus AM Prince 2000 DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins J Infect Dis 182 1 18 27 10.1086/315646 1:CAS:528:DC%2BD3cXlvVygsLc%3D 10882577 (Pubitemid 30497784)
38. SW Barnett JM Klinger B Doe CM Walker L Hansen AM Duliege, et al. 1998 Prime-boost immunization strategies against HIV AIDS Res Hum Retrovir 14 Suppl 3 S299 S309 1:CAS:528:DyaK1cXnsVWqtrc%3D 9814958
39. SJ Dunachie AV Hill 2003 Prime-boost strategies for malaria vaccine development J Exp Biol 206 Pt 21 3771 3779 10.1242/jeb.00642 1:CAS:528:DC%2BD3sXpsFChtrc%3D 14506212 (Pubitemid 37365459)
40. AJ McMichael 2006 HIV vaccines Annu Rev Immunol 24 227 255 10.1146/annurev.immunol.24.021605.090605 1:CAS:528:DC%2BD28XkvFSqt7g%3D 16551249
41. AC Moore AV Hill 2004 Progress in DNA-based heterologous prime-boost immunization strategies for malaria Immunol Rev 199 126 143 10.1111/j.0105-2896. 2004.00138.x 1:CAS:528:DC%2BD2cXltFygsL0%3D 15233731 (Pubitemid 38736768)